WO2014159244A3 - Anticorps tau d'o-glcnac et son utilisation - Google Patents

Anticorps tau d'o-glcnac et son utilisation Download PDF

Info

Publication number
WO2014159244A3
WO2014159244A3 PCT/US2014/022660 US2014022660W WO2014159244A3 WO 2014159244 A3 WO2014159244 A3 WO 2014159244A3 US 2014022660 W US2014022660 W US 2014022660W WO 2014159244 A3 WO2014159244 A3 WO 2014159244A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
glcnac
tau antibody
relates
glcnacylated
Prior art date
Application number
PCT/US2014/022660
Other languages
English (en)
Other versions
WO2014159244A2 (fr
Inventor
Heike HERING
Mohanraj Dhanabal
Mei Zhang
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of WO2014159244A2 publication Critical patent/WO2014159244A2/fr
Publication of WO2014159244A3 publication Critical patent/WO2014159244A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un anticorps qui est capable de se lier à l'isoforme tau d'O-GlcNacylé 2N4R au niveau de la sérine 400. Un autre objet de l'invention concerne l'utilisation dudit anticorps pour cribler des molécules pour identifier une activité inhibitrice d'OGA, et un procédé d'administration d'une molécule thérapeutique à un patient ayant besoin d'un traitement contre la maladie d'Alzheimer. L'invention concerne également un procédé de préparation d'un anticorps monoclonal de lapin.
PCT/US2014/022660 2013-03-14 2014-03-10 Anticorps tau d'o-glcnac et son utilisation WO2014159244A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361782353P 2013-03-14 2013-03-14
US61/782,353 2013-03-14
US201361817556P 2013-04-30 2013-04-30
US61/817,556 2013-04-30
US201361836460P 2013-06-18 2013-06-18
US61/836,460 2013-06-18

Publications (2)

Publication Number Publication Date
WO2014159244A2 WO2014159244A2 (fr) 2014-10-02
WO2014159244A3 true WO2014159244A3 (fr) 2014-11-27

Family

ID=50686104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/022660 WO2014159244A2 (fr) 2013-03-14 2014-03-10 Anticorps tau d'o-glcnac et son utilisation

Country Status (1)

Country Link
WO (1) WO2014159244A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014008404A1 (fr) 2012-07-03 2014-01-09 Washington University Anticorps dirigés contre tau
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
WO2016026143A1 (fr) 2014-08-22 2016-02-25 Huiru Wang Biomarqueurs à base de saccharide et produits thérapeutiques
WO2017139975A1 (fr) 2016-02-19 2017-08-24 Huiru Wang Anticorps dirigés contre la n-acétylglucosamine et la n-acétylgalactosamine
GB201909393D0 (en) 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
CN111234022B (zh) * 2019-12-16 2024-03-22 江苏省药物研究所有限公司 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAMERON ANDREW ET AL: "Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400", FEBS LETTERS, vol. 587, no. 22, 7 October 2013 (2013-10-07), pages 3722 - 3728, XP028766008, ISSN: 0014-5793, DOI: 10.1016/J.FEBSLET.2013.09.042 *
CHIN FEN TEO ET AL: "Glycopeptide-specific monoclonal antibodies suggest new roles for O-GlcNAc", NATURE CHEMICAL BIOLOGY, vol. 6, no. 5, 21 March 2010 (2010-03-21), pages 338 - 343, XP055128488, ISSN: 1552-4450, DOI: 10.1038/nchembio.338 *
SCOTT A YUZWA ET AL: "Mapping-GlcNAc modification sites on tau and generation of a site-specific-GlcNAc tau antibody", AMINO ACIDS ; THE FORUM FOR AMINO ACID AND PROTEIN RESEARCH, SPRINGER-VERLAG, VI, vol. 40, no. 3, 13 August 2010 (2010-08-13), pages 857 - 868, XP019883381, ISSN: 1438-2199, DOI: 10.1007/S00726-010-0705-1 *
SCOTT A. YUZWA ET AL: "O-GlcNAc Modification of tau Directly Inhibits Its Aggregation without Perturbing the Conformational Properties of tau Monomers", JOURNAL OF MOLECULAR BIOLOGY, vol. 426, no. 8, 1 April 2014 (2014-04-01), pages 1736 - 1752, XP055128286, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2014.01.004 *

Also Published As

Publication number Publication date
WO2014159244A2 (fr) 2014-10-02

Similar Documents

Publication Publication Date Title
PH12018500062A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2014159244A3 (fr) Anticorps tau d'o-glcnac et son utilisation
MX356800B (es) Anticuerpo tau humanizado.
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
PH12018502613A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2014031694A3 (fr) Anticorps anti-tau et procédés de préparation et d'utilisation dans le traitement de tauopathies
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
WO2014144763A3 (fr) Anticorps anti-gd2 à haute affinité
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
AU2018256498A1 (en) Antibodies to amyloid beta
WO2016012285A3 (fr) Procédé
GEP20217253B (en) ANTIBODIES TO α-SYNUCLEIN AND USES THEREOF
MY164376A (en) Phosphospecific antibodies recognizing tau
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
EA201690898A1 (ru) Способы лечения таупатии
MY184890A (en) Improved a? protofibril binding antibodies
EA201300130A1 (ru) Способ лечения болезни альцгеймера
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
EA201990895A1 (ru) Антитела к о1 и варианты их применения
WO2015117088A3 (fr) Réactifs à base d'anticorps qui reconnaissent spécifiquement les formes de la protéine tdp-43 associées à une maladie neurodégénérative
EA201290671A1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
WO2015001013A3 (fr) Anticorps anti-ifn-alpha humains
WO2014053110A3 (fr) Peptide pour le traitement et le diagnostic précoce de la maladie d'alzheimer et d'autres tauopathies
EP2987496A4 (fr) Agent de traitement des troubles cognitifs, basé sur la protéine bêta-amyloïde, agent thérapeutique contre la maladie d'alzheimer et procédé de traitement et procédé d'analyse pathologique correspondants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14722813

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14722813

Country of ref document: EP

Kind code of ref document: A2